Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Nicola C EdwardsAnna M PriceSamir MehtaThomas F HiemstraAmreen KaurPeter J GreasleyDavid J WebbNeeraj DhaunIain M MacIntyreTariq FarrahVanessa MelvilleAnna S HerreyGemma SlinnRebekah WaleNatalie IvesDavid C WheelerIan WilkinsonRichard P SteedsCharles J FerroJonathan N TownendPublished in: Clinical journal of the American Society of Nephrology : CJASN (2021)
Spironolactone was not superior to chlorthalidone in reducing left ventricular mass, BP, or arterial stiffness in nondiabetic CKD.
Keyphrases
- open label
- phase iii
- phase ii
- left ventricular
- study protocol
- clinical trial
- chronic kidney disease
- blood pressure
- phase ii study
- heart failure
- acute myocardial infarction
- cardiac resynchronization therapy
- randomized controlled trial
- left atrial
- mitral valve
- aortic stenosis
- double blind
- squamous cell carcinoma
- placebo controlled
- atrial fibrillation
- percutaneous coronary intervention
- ejection fraction
- acute coronary syndrome